Effect of inhibiting HMG-CoA reductase on 7α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: Contrasting findings in patients with and without prior up-regulation of the latter pathway

European Journal of Clinical Investigation

Volumn 29, Issue 5, 1999, Pages 404-412

  Naoumova, R P ^a   O'Neill, F H ^a   Dunn, S ^a   Neuwirth, C K Y ^a   Taylor, G W ^a   Axelson, M ^b   Thompson, G R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

7 hydroxy 4 cholesten 3 one; Atorvastatin; Cholesterol; Familial hypercholesterolaemia; Mevalonic acid; Partial ileal bypass

Indexed keywords

ATORVASTATIN; BILE ACID; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ILEUM BYPASS; MALE; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; CHOLESTENONES; FEMALE; HEPTANOIC ACIDS; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; JEJUNOILEAL BYPASS; LIPIDS; LIPOPROTEINS; MALE; MEVALONIC ACID; MIDDLE AGED; PYRROLES; UP-REGULATION;

EID: 0032954448     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00475.x     Document Type: Article

References (37)

1. 1 Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
2. 2 Myant NB. Cholesterol metabolism, LDL and the LDL receptor San Diego: Academic Press; 1990.
3. 3 Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993;34:1637-59.
4. 4 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. 5 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
6. 6 Sacks FM, Pfeffer MA, Moye LA, et al. and for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
7. 7 Grundy SM. HMG CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
8. 8 Reihner E, Rudling M, Stahlberg D, et al. Influence of pravastatin, a specific inhibitor of HMG CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990;323:224-8.
9. 9 Duane WC. Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects. J Clin Invest 1993;92:911-8.
10. 10 Grundy SM, Bilheimer DW. Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: Effects on cholesterol balance. Proc Natl Acad Sci USA 1984;81:2538-42.
11. 11 Mazella G, Parini P, Festi D, et al. Effects of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in non-familial hypercholesterolemia. Hepatology 1992;15:1072-8.
12. 12 Duane WC. Effects of lovastatin and dietary cholesterol on bile acid kinetics and bile lipid composition in healthy subjects. J Lipid Res 1994;35:501-9.
13. 13 Vanhanen H, Kesaniemi YA, Miettinen TA. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids and cholesterol absorption in man. Metabolism 1992;41:588-95.
14. 14 Mitchell JC, Stone BG, Logan GM, Duane WC. Role of cholesterol synthesis in regulation of bile acid synthesis and biliary cholesterol secretion in humans. J Lipid Res 1991;32:1143-9.
15. 15 Muraca M, Baggio G, Miconi L, et al. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation. Eur J Clin Invest 1991;21:204-8.
16. 16 Loria P, Bertolotti M, Cassinadri MT, et al. Short term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. Hepatology 1994;19:882-8.
17. 17 Hillebrant C-G, Eriksson M, Nyberg B, Einarsson K. Changes in biliary lipid output after interruption of pravastatin treatment in humans. Eur J Clin Invest 1996;26:1160-5.
18. 18 Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
19. 19 Auerbach BJ, Krause BR, Bisgaier CL, Newton RS. Comparative effects of HMG-CoA reductase inhibitors on apoB production in the casein-fed rabbit: atorvastatin versus lovastatin. Atherosclerosis 1995;115:173-80.
20. 20 Naoumova RP, Marais AD, Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996;119:203-13.
21. 21 Naoumova RP, Dunn S, Rallidis L, et al. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 1997;38:1496-500.
22. 22 Parker TS, McNamara DJ, Brown CD, et al. Plasma mevalonate as a measure of cholesterol synthesis in man. J Clin Invest 1984;74:795-804.
23. 23 Yoshida T, Honda A, Tanaka N, et al. Simultaneous determination of mevalonate and 7 alpha-hydroxycholesterol in human plasma by gas chromatography-mass spectrometry as indices of cholesterol and bile acid biosynthesis. J Chromatogr 1993;613:185-93.
24. 24 Jones PJ, Pappu AS, Illingworth DR, Leitch CA. Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis. Eur J Clin Invest 1992;22:609-13.
25. 25 Axelson M, Aly A, Sjövall J. Levels of 7α-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man. FEBS Lett 1988;239:324-8.
26. 26 Axelson M, Björkhem I, Reihnér E, Einarsson K. The plasma level of 7αhydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7αhydroxylase in man. FEBS Lett 1991;284:216-8.
27. 27 Recommendations for treatment of hyperlipidaemia in adults. A joint statement of the Nutrition Committee and the Council on Atherosclerosis. Circulation 1984;69:1065A-1090A.
28. 28 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
29. 29 Pappu AS, Illingworth DR. Contrasting effects of lovastatin and cholestyramine on low-density cholesterol and 24-h urinary mevalonate excretion in patients with heterozygous familial hypercholesterolaemia. J Lab Clin Med 1989;114:554-62.
30. 30 Parker TS, McNamara DJ, Brown C, et al. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA 1982;79:3037-41.
31. 31 Sauter G, Berr F, Beuers U, Fischer S, Paumgartner G. Serum concentrations of 7α-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 1996;26:1160-5.
32. 32 Eusufzai S, Axelson M, Angelin B, Einarsson K. Serum 7αhydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test. Gut 1993;34:698-701.
33. 33 Axelson M, Sjövall J. Potential bile acid precursors in plasma: possible indicators of biosynthetic ways to cholic and chenodcoxycholic acids in man. J Steroid Biochem 1990;36:631-40.
34. 34 Shoda J, Toll A, Axelson M, Pieper F, Wikvall K, Sjövall J. Formation of 7α and 7β-hydroxylated bile acid precursors from 27-hydroxycholesterol in human liver microsomes and mitochondria. Hepatology 1993;17:395-403.
35. 35 Schwarz M, Lund EG, Russell DW. Two 7α-hydroxylase enzymes in bile acid biosynthesis. Curr Opin Lipidol 1998;9:113-8.
36. 36 Hillebrant C-G, Axelson M, Björkhem I, Wang F-H, Nyberg B, Einarsson C. Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients. Eur J Clin Invest 1998;28:324-8.
37. 37 Bertolotti M, Abate N, Loria P, et al. Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7αhydroxylation rates In Vivo Hepatol 1991;14:830-7.